ENVB — Enveric Biosciences, Inc.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 5
- Website: https://www.enveric.com
Latest SEC filings for ENVB
- 8-K — 2026-06-09
- 8-K — 2026-06-09
- 424B5 — 2026-06-09
- 424B5 — 2026-06-09
- 8-K — 2026-05-29
- 8-K — 2026-05-15
- 10-Q — 2026-05-15
- D — 2026-05-04
- EFFECT — 2026-04-30
- 8-K — 2026-04-30
Educational tool only — not investment advice.